Mkt Perform $10
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) upgraded to Mkt Perform with price target $10 by FBR Capital
FBR Capital upgraded Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) to Mkt Perform with
price target $10. Previously, FBR Capital rated Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) to Underperform on 12/02/2014, when the stock price was valued at $15.45.
Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.
uses a highly disciplined analysis focused on intrinsic value, which we developed to critically examine the capital structure of the companies we cover, as well as their competitive positions and the growth opportunities within their industries. We apply this discipline – which helps us assess how effectively a company’s managers deploy the capital entrusted to them – not only in our published research but also when making investing and underwriting judgments.